MX2020000491A - Moduladores terapeuticos del modo inverso de la atp sintasa. - Google Patents

Moduladores terapeuticos del modo inverso de la atp sintasa.

Info

Publication number
MX2020000491A
MX2020000491A MX2020000491A MX2020000491A MX2020000491A MX 2020000491 A MX2020000491 A MX 2020000491A MX 2020000491 A MX2020000491 A MX 2020000491A MX 2020000491 A MX2020000491 A MX 2020000491A MX 2020000491 A MX2020000491 A MX 2020000491A
Authority
MX
Mexico
Prior art keywords
atp synthase
reverse mode
therapeutic modulators
atp
modulators
Prior art date
Application number
MX2020000491A
Other languages
English (en)
Inventor
Michael David Forrest
Original Assignee
Michael David Forrest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2018/051127 external-priority patent/WO2018134265A1/en
Application filed by Michael David Forrest filed Critical Michael David Forrest
Priority claimed from PCT/EP2018/069175 external-priority patent/WO2019012149A1/en
Publication of MX2020000491A publication Critical patent/MX2020000491A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los compuestos que lenta el modo de ATP-hidrolizar de la ATP sintasa son útiles para tratar diversas enfermedades y trastornos, incluyendo el cáncer, particularmente cánceres que utilizan el efecto Warburg.
MX2020000491A 2017-07-13 2018-07-13 Moduladores terapeuticos del modo inverso de la atp sintasa. MX2020000491A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1711250.9A GB201711250D0 (en) 2017-07-13 2017-07-13 Cancer therapy
PCT/EP2018/051127 WO2018134265A1 (en) 2017-01-17 2018-01-17 Therapeutic inhibitors of the reverse mode of atp synthase
PCT/EP2018/069175 WO2019012149A1 (en) 2017-07-13 2018-07-13 THERAPEUTIC MODULATORS OF THE INVERSE MODE OF ATP SYNTHASE

Publications (1)

Publication Number Publication Date
MX2020000491A true MX2020000491A (es) 2020-10-28

Family

ID=59713660

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000491A MX2020000491A (es) 2017-07-13 2018-07-13 Moduladores terapeuticos del modo inverso de la atp sintasa.

Country Status (3)

Country Link
KR (1) KR20200078472A (es)
GB (1) GB201711250D0 (es)
MX (1) MX2020000491A (es)

Also Published As

Publication number Publication date
KR20200078472A (ko) 2020-07-01
GB201711250D0 (en) 2017-08-30

Similar Documents

Publication Publication Date Title
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
PH12019501959A1 (en) Therapeutic rna
MX2022000789A (es) Compuestos heterociclicos como inmunomoduladores.
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
JOP20200152A1 (ar) مركبات حلقية كبرى لعلاج مرض
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
PH12015502028A1 (en) Ido inhibitors
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
MX2017004128A (es) Derivados de diarilurea como inhibidores de quinasa p38.
PH12015502161A1 (en) Therapeutic compounds and compositions
EP3565558A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2018010993A (es) Derivados de icariina e icaritina.
AU2018380132A8 (en) Tubulin inhibitors
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
PH12021550035A1 (en) Combination therapy
NZ740817A (en) Pcna inhibitors